CytoMed Therapeutics (GDTC) Competitors $2.30 -0.30 (-11.39%) Closing price 03/26/2025 03:55 PM EasternExtended Trading$2.30 +0.01 (+0.26%) As of 03/26/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsSEC FilingsShort InterestTrendsBuy This Stock GDTC vs. SGMT, COYA, NKTX, DERM, ELUT, KYTX, FATE, PROC, CHRS, and PLRXShould you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include Sagimet Biosciences (SGMT), Coya Therapeutics (COYA), Nkarta (NKTX), Journey Medical (DERM), Elutia (ELUT), Kyverna Therapeutics (KYTX), Fate Therapeutics (FATE), Procaps Group (PROC), Coherus BioSciences (CHRS), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical products" industry. CytoMed Therapeutics vs. Sagimet Biosciences Coya Therapeutics Nkarta Journey Medical Elutia Kyverna Therapeutics Fate Therapeutics Procaps Group Coherus BioSciences Pliant Therapeutics Sagimet Biosciences (NASDAQ:SGMT) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, profitability, risk and institutional ownership. Which has more risk & volatility, SGMT or GDTC? Sagimet Biosciences has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500. Comparatively, CytoMed Therapeutics has a beta of -0.94, meaning that its share price is 194% less volatile than the S&P 500. Is SGMT or GDTC more profitable? CytoMed Therapeutics' return on equity of 0.00% beat Sagimet Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Sagimet BiosciencesN/A -23.63% -22.91% CytoMed Therapeutics N/A N/A N/A Which has higher earnings and valuation, SGMT or GDTC? CytoMed Therapeutics has lower revenue, but higher earnings than Sagimet Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSagimet Biosciences$2M60.58-$27.88M-$1.43-2.76CytoMed TherapeuticsN/AN/A-$3.13MN/AN/A Do institutionals & insiders believe in SGMT or GDTC? 87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 17.6% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate SGMT or GDTC? Sagimet Biosciences currently has a consensus target price of $22.40, suggesting a potential upside of 467.09%. CytoMed Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 117.86%. Given Sagimet Biosciences' higher possible upside, equities analysts clearly believe Sagimet Biosciences is more favorable than CytoMed Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sagimet Biosciences 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80CytoMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in SGMT or GDTC? Sagimet Biosciences received 23 more outperform votes than CytoMed Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CytoMed Therapeutics an outperform vote while only 96.43% of users gave Sagimet Biosciences an outperform vote. CompanyUnderperformOutperformSagimet BiosciencesOutperform Votes2796.43% Underperform Votes13.57%CytoMed TherapeuticsOutperform Votes4100.00% Underperform VotesNo Votes Does the media refer more to SGMT or GDTC? In the previous week, Sagimet Biosciences had 2 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 4 mentions for Sagimet Biosciences and 2 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.44 beat Sagimet Biosciences' score of 0.77 indicating that CytoMed Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Sagimet Biosciences Positive CytoMed Therapeutics Positive SummarySagimet Biosciences beats CytoMed Therapeutics on 8 of the 14 factors compared between the two stocks. Remove Ads Get CytoMed Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GDTC vs. The Competition Export to ExcelMetricCytoMed TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.11M$6.90B$5.62B$8.13BDividend YieldN/A2.73%4.56%4.00%P/E RatioN/A7.1824.5419.09Price / SalesN/A226.87386.7694.71Price / CashN/A65.6738.1634.64Price / Book2.946.486.974.36Net Income-$3.13M$142.41M$3.20B$247.23M7 Day Performance-13.07%-2.89%-2.19%-0.34%1 Month Performance-16.55%-4.52%3.14%-3.60%1 Year Performance2.46%-8.69%11.39%2.01% CytoMed Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GDTCCytoMed Therapeutics2.4968 of 5 stars$2.30-11.4%$5.00+117.9%+9.8%$25.11MN/A0.00N/AShort Interest ↓Positive NewsGap DownSGMTSagimet Biosciences2.8183 of 5 stars$3.78+1.1%$23.00+508.5%-24.5%$115.95M$2M-2.648Short Interest ↓COYACoya Therapeutics2.1555 of 5 stars$6.85+5.5%$16.25+137.2%-26.4%$114.44M$9.55M-10.546Analyst RevisionNKTXNkarta2.5818 of 5 stars$1.62-2.4%$15.00+825.9%-86.1%$114.32MN/A-0.86140Earnings ReportNews CoverageDERMJourney Medical2.6055 of 5 stars$5.31+1.1%$9.67+82.0%+66.4%$110.93M$57.77M-5.6590News CoverageELUTElutia3.9876 of 5 stars$3.20+0.6%$9.00+181.3%-19.3%$110.60M$24.38M-1.23180Short Interest ↓KYTXKyverna Therapeutics1.4947 of 5 stars$2.54+1.6%$18.40+624.4%-89.9%$109.66M$7.03M0.0096FATEFate Therapeutics3.9606 of 5 stars$0.97+2.6%$5.50+469.2%-87.5%$107.89M$13.63M-0.59550Positive NewsPROCProcaps GroupN/A$0.95-40.3%N/A-68.3%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeCHRSCoherus BioSciences3.6295 of 5 stars$0.92-0.5%$5.38+487.0%-60.7%$106.12M$266.96M-11.45330PLRXPliant Therapeutics4.3262 of 5 stars$1.70+10.4%$13.31+683.1%-89.6%$104.10M$1.58M-0.5190Short Interest ↑High Trading Volume Remove Ads Related Companies and Tools Related Companies SGMT Competitors COYA Competitors NKTX Competitors DERM Competitors ELUT Competitors KYTX Competitors FATE Competitors PROC Competitors CHRS Competitors PLRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GDTC) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GDTC Stock Free GDTC Stock Alerts